Issues around Paxlovid – Part 1

Available through an FDA Emergency Use Authorization (EUA), Paxlovid could be a approach to more effective treatment of the COVID-19 virus. On this episode, we begin a two-part discussion about the evidence from clinical trials of Paxlovid.

 

Guest speaker:
Stacy Lauderdale, PharmD, BCPS
Senior Director, Drug Information
Vizient

 

Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Senior Principal, Clinical Operations and Quality
Vizient

 

Show Notes:

[01:09] Defining Paxlovid

[01:53] Paxlovid vs Tamiflu – comparison of effectiveness and impact

[02:50] Two randomized control trials

[04:42] Effectiveness with Omicron variant

[07:19] Age as a risk factor

[08:23] The issue of rebound

 

Links | Resources:

To contact Modern Practice: modernpracticepodcast@vizientinc.com

Stacy’s email address: stacy.lauderdale@vizientinc.com

13 Things to Know about Paxlovid, the Latest COVID-19 Pill (Yale Medicine) Click here

 

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Android

Google Podcasts

Spotify

Stitcher

RSS Feed